

 



<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:foaf="http://xmlns.com/foaf/0.1/"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
      xmlns:xsd="http://www.w3.org/2001/XMLSchema-datatypes#"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">
<head prefix="og: http://ogp.me/ns#">
  <title>PLOS ONE: Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya</title>


<link rel="stylesheet" type="text/css"  href="/css/global-min.css?v=izteQ6tu7kgsJZW_xmrYizvKiHM" />


    <!--[if lte IE 7]>
<link rel="stylesheet" type="text/css"  href="/css/lte_ie7-min.css?v=3bykQUyQmReeuobVyPozcJ9LxRc" />
    <![endif]-->


<link rel="stylesheet" type="text/css"  href="/css/jquery-ui-min.css?v=eXDHTEJM0lIAmDe5k0I0Ad4nxNo" />


<link rel="stylesheet" type="text/css"  href="/css/journal.css?v=T7ZVxJfgk9jNxLAJ2qHz1vZpgYU" />


<link rel="stylesheet" type="text/css" media="print" href="/css/print-min.css?v=T5lb0B3q6EXBsuDluc5V5w+AkRc" />


  <link rel="stylesheet" href="http://f.fontdeck.com/s/css/js/www.plosone.org/24557.css" type="text/css"/>

  <!--chartbeat -->
  <script type="text/javascript">var _sf_startpt = (new Date()).getTime()</script>
  <script>document.documentElement.className += ' js';</script>

  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7; IE=EmulateIE9"/>
  <meta name="description" content="PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world."/>
  <meta name="keywords" content="PLOS, Public Library of Science, Open Access, Open-Access, Science, Medicine, Biology, Research, Peer-review, Inclusive, Interdisciplinary, Ante-disciplinary, Physics, Chemistry, Engineering"/>
  <meta name="almHost" content="http://alm.plos.org/api/v3/articles"/>
  <meta name="searchHost" content="http://api.plos.org/search" />
  <meta name="termsHost" content="http://api.plos.org/terms" />
  <meta name="solrApiKey" content="plos"/>
  <meta name="almAPIKey" content="3pezRBRXdyzYW6ztfwft" />
  <meta name="currentJournal" content="PLoSONE" />
  <meta name="almRequestBatchSize" content="" />

  <meta name="citation_publisher" content="Public Library of Science"/>
  <meta name="citation_doi" content="10.1371/journal.pone.0000707"/>
  <meta name="dc.identifier" content="10.1371/journal.pone.0000707" />

    <meta name="citation_title" content="Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya"/>
    <meta itemprop="name" content="Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya"/>

      <meta name="citation_author" content="Philip Bejon"/>
            <meta name="citation_author_institution" content="Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya"/>
      <meta name="citation_author" content="Edna Ogada"/>
            <meta name="citation_author_institution" content="Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya"/>
      <meta name="citation_author" content="Tabitha Mwangi"/>
            <meta name="citation_author_institution" content="Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya"/>
            <meta name="citation_author_institution" content="Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom"/>
      <meta name="citation_author" content="Paul Milligan"/>
            <meta name="citation_author_institution" content="London School of Hygiene and Tropical Medicine, London, United Kingdom"/>
      <meta name="citation_author" content="Trudie Lang"/>
            <meta name="citation_author_institution" content="Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom"/>
      <meta name="citation_author" content="Greg Fegan"/>
            <meta name="citation_author_institution" content="Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya"/>
            <meta name="citation_author_institution" content="London School of Hygiene and Tropical Medicine, London, United Kingdom"/>
      <meta name="citation_author" content="Sarah C. Gilbert"/>
            <meta name="citation_author_institution" content="Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom"/>
      <meta name="citation_author" content="Norbert Peshu"/>
            <meta name="citation_author_institution" content="Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya"/>
      <meta name="citation_author" content="Kevin Marsh"/>
            <meta name="citation_author_institution" content="Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya"/>
            <meta name="citation_author_institution" content="Nuffield Department of Clinical Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom"/>
      <meta name="citation_author" content="Adrian V.S. Hill"/>
            <meta name="citation_author_institution" content="Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom"/>
            <meta name="citation_author_institution" content="Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom"/>

    <meta name="citation_date" content="2007/8/15"/>

  <meta name="citation_pdf_url" content="http://dx.plos.org/10.1371/journal.pone.0000707.pdf" />

      <meta name="citation_journal_title" content="PLOS ONE" />
    <meta name="citation_firstpage" content="e707"/>
    <meta name="citation_issue" content="8"/>
    <meta name="citation_volume" content="2"/>
    <meta name="citation_issn" content="1932-6203"/>

    <meta name="citation_journal_abbrev" content="PLoS ONE" />

      <meta name="citation_reference" content="citation_title=The global distribution of clinical episodes of Plasmodium falciparum malaria.; citation_author=RW Snow; citation_author=CA Guerra; citation_author=AM Noor; citation_author=HY Myint; citation_author=SI Hay; citation_journal_title=Nature; citation_volume=434; citation_number=1; citation_pages=214-217; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=A protein particle vaccine containing multiple malaria epitopes.; citation_author=SC Gilbert; citation_author=M Plebanski; citation_author=SJ Harris; citation_author=CE Allsopp; citation_author=R Thomas; citation_journal_title=Nat Biotechnol; citation_volume=15; citation_number=2; citation_pages=1280-1284; citation_date=1997; " />
      <meta name="citation_reference" content="citation_title=Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.; citation_author=DP Webster; citation_author=S Dunachie; citation_author=JM Vuola; citation_author=T Berthoud; citation_author=S Keating; citation_journal_title=Proc Natl Acad Sci U S A; citation_volume=102; citation_number=3; citation_pages=4836-4841; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya.; citation_author=P Bejon; citation_author=J Mwacharo; citation_author=O Kai; citation_author=T Mwangi; citation_author=P Milligan; citation_journal_title=PLoS Clin Trials; citation_volume=1; citation_number=4; citation_pages=e29; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1–6 year old children in a malaria endemic area.; citation_author=P Bejon; citation_author=J Mwacharo; citation_author=OK Kai; citation_author=S Todryk; citation_author=S Keating; citation_number=5; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection.; citation_author=M Walther; citation_author=JE Tongren; citation_author=L Andrews; citation_author=D Korbel; citation_author=E King; citation_journal_title=Immunity; citation_volume=23; citation_number=6; citation_pages=287-296; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Cellular reactivity to the P. falciparum protein TRAP in adult Kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation.; citation_author=KL Flanagan; citation_author=M Plebanski; citation_author=K Odhiambo; citation_author=E Sheu; citation_author=T Mwangi; citation_journal_title=Am J Trop Med Hyg; citation_volume=74; citation_number=7; citation_pages=367-375; citation_date=2006; " />

  <link rel="canonical" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000707" />

    <meta name="twitter:card" content="summary"/>
    <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya"/>
    <meta name="twitter:description" content="
Background
&ldquo;FFM ME-TRAP&rdquo; is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara) delivering the pre-erythrocytic malaria antigen ME-TRAP. Over nine months follow-up in our original study, there was no evidence that FFM ME-TRAP provided protection against malaria. The incidence of malaria was slightly higher in children who received FFM ME-TRAP, but this was not statistically significant (hazard ratio 1.5, 95% CI 1.0-2.3). Although the study was unblinded, another nine months follow-up was planned to monitor the incidence of malaria and other serious adverse events.

Methods and Findings
405 children aged 1&ndash;6 yrs were initially randomized to vaccination with either FFM ME-TRAP or control (rabies vaccine). 380 children were still available for follow-up after the first nine months. Children were seen weekly and whenever they were unwell for nine months monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to parasitaemia &gt;2,500/&micro;l. During the second nine months monitoring, 49 events met the primary endpoint (febrile malaria with parasites &gt;2,500/&micro;l) in the Intention To Treat (ITT) group. 23 events occurred among the 189 children in the FFM ME-TRAP group, and 26 among the 194 children in the control group. In the full 18 months of monitoring, there were 63 events in the FFM ME-TRAP group and 60 in the control group (HR&#8202;=&#8202;1.2, CI 0.84-1.73, p&#8202;=&#8202;0.35). There was no evidence that the HR changed over the 18 months (test for interaction between time and vaccination p&#8202;=&#8202;0.11).

Conclusions
Vaccination with FFM ME-TRAP was not protective against malaria in this study. Malaria incidence during 18 months of surveillance was similar in both vaccine groups.

Trial Registration
Controlled-Trials.com ISRCTN88335123
"/>
      <meta name="twitter:image" content="http://dx.plos.org/10.1371/journal.pone.0000707.g002"/>

  <meta property="og:title" content="Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya" />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000707" />

 <!--end articleInfoX-->

  <link rel="pingback" href="http://www.plosone.org/pingback" />


  <link rel="shortcut icon" href="/images/favicon.ico" type="image/x-icon"/>
  <link rel="home" title="home" href="/"/>
  <link rel="alternate" type="application/rss+xml"
        title="PLOS ONE: New Articles"
        href="http://www.plosone.org/article/feed"/>
</head>
<body>

  <div id="page-wrap">
    <div id="topbanner" class="cf">

<!-- Div for the ad at the top of journal home page-->
<div class="center">
  <div class="title">Advertisement</div>
  <iframe id='a3ac9da4' name='a3ac9da4'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=345&amp;cb=3191'
    frameborder='0' scrolling='no' width='730' height='90'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a3ac9da4&amp;cb=4951'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=345&amp;cb=4379&amp;n=a3ac9da4'
      border='0' alt=''/>
    </a>
  </iframe>
</div>    </div>

    <div id="pagehdr-wrap">
      <div id="pagehdr">
        <div id="user" class="nav">
          <ul>
            <li><a href="http://www.plos.org">plos.org</a></li>
            <li><a href="https://register.plos.org/ambra-registration/register.action">create account</a></li>
            <li class="btn-style"><a
              href="/user/secure/secureRedirect.action?goTo=%2Farticle%2FfetchArticle.action%3FarticleURI%3Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0000707">sign in</a>
            </li>
          </ul>
        </div>
        <div class="logo">
          <a href="/"><img src="/images/logo.png" alt="PLOS ONE"></a>
        </div>

<div id="nav-main" class="nav">
  <ul>
        <li id="mn-01"><a href="/taxonomy" class="areas-link">Subject Areas</a></li>
    <li id="mn-02"><a href="javascript:void(0);">For Authors</a>
      <div class="submenu" style="width: 540px; margin-left: -300px;">
        <div class="block">
          <div class="submit-script">
            <h3>Submit your Manuscript</h3>
            <ul>
              <li>Fair, rigorous peer review</li>
              <li>Broad scope and wide reach</li>
            </ul>
            <a href="/static/submissionInstructions" class="btn">get started</a>
          </div>
        </div>
        <div class="menu">
          <ul>
            <li><a href="/static/publish">Why Publish with PLOS ONE</a></li>
            <li><a href="/static/publication">Publication Criteria</a></li>
            <li><a href="/static/editorial">Editorial Policies</a></li>
            <li><a href="/static/guidelines">Preparing A Manuscript</a></li>
            <li><a href="/static/figureGuidelines">Figure and Table Guidelines</a></li>
          <li><a href="/static/supportingInformation">Supporting Information Guidelines</a></li>
            <li><a href="/static/submissionInstructions">Submitting a Manuscript</a></li>
          </ul>
        </div>
      </div>
    </li>

    <li id="mn-03"><a href="javascript:void(0);">About Us</a>
      <div class="submenu" style="width:248px; margin-left:-30px;">
        <div class="menu">
          <ul>
            <li><a href="/static/information">Journal Information</a></li>
            <li><a href="/static/edboard">Editorial Board</a></li>
            <li><a href="/static/reviewerGuidelines">Reviewer Guidelines</a></li>
            <li><a href="/static/almInfo">Article-Level Metrics</a></li>
            <li><a href="/static/license">Open-Access License</a></li>
            <li><a href="/static/downloads">Media Downloads</a></li>
            <li><a href="/static/commentGuidelines">Guidelines for Comments</a></li>
            <li><a href="/static/corrections">Corrections</a></li>
            <li><a href="/static/help">Help Using this Site</a></li>
            <li><a href="/static/contact">Contact Us</a></li>
          </ul>
        </div>
      </div>
    </li>
  </ul>
<div id="db">
  <form name="searchForm" action="/search/simple?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000707" method="get" >
<input type="hidden" name="from" value="globalSimpleSearch" id="from"/><input type="hidden" name="filterJournals" value="PLoSONE" id="filterJournals"/>    <fieldset>
      <legend>Search</legend>
      <label for="search">Search</label>
      <div class="wrap">
        <input id="search" type="text" name="query" placeholder="Search">
        <input type="image" alt="SEARCH" src="/images/icon.search.gif">
      </div>
    </fieldset>
  </form>
    <a id="advSearch" href="/search/advanced?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000707&filterJournals=PLoSONE">advanced search</a>
</div></div>

      </div>
      <!-- pagehdr-->
    </div>
    <!-- pagehdr-wrap -->

  <!--body and html tags gets closed in global_footer.ftl-->
<script type="text/javascript" src="/javascript/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>

<div id="pagebdy-wrap">
  <div id="pagebdy">

    <div id="article-block" class="cf">

<div class="article-meta cf">
  <ul id="almSignPost" style="display: none;"></ul>
  <div class="article-type">
    <span class="type oa">Open Access</span>
      <span class="type pr">Peer-Reviewed</span>
  </div>
</div>

<div class="header" id="hdr-article">

<div class="article-kicker">
      <span id="article-type-heading">
        Research Article
      </span>
</div>  <h1 property="dc:title" datatype="" rel="dc:type" href="http://purl.org/dc/dcmitype/Text">
    Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
  </h1>

  <ul class="authors">
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Philip Bejon
              <span class="corresponding">mail</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">*</span>To whom correspondence should be addressed. E-mail: <a href="mailto:pbejon@well.ox.ac.uk">pbejon@well.ox.ac.uk</a></p>

                <p>Affiliation:
                  Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Edna Ogada, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Tabitha Mwangi, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya, 
                  Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Paul Milligan, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  London School of Hygiene and Tropical Medicine, London, United Kingdom
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Trudie Lang, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Greg Fegan, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya, 
                  London School of Hygiene and Tropical Medicine, London, United Kingdom
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Sarah C. Gilbert, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Norbert Peshu, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Kevin Marsh, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya, 
                  Nuffield Department of Clinical Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Adrian V.S. Hill
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom, 
                  Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
  </ul>
  <ul class="date-doi-line">
    <li>Published: August 15, 2007</li>
    <li>DOI: 10.1371/journal.pone.0000707</li>
  </ul>


</div><!--end header-->
<div class="main cf" id="pjax-container">
  

<div class="nav items-5" id="nav-article">
  <ul>
  <li>
        <span class="active" name="article">Article</span>
  </li>
  <li>
      <a href="/article/authors/info%3Adoi%2F10.1371%2Fjournal.pone.0000707" name="authors">About the Authors</a>
  </li>
  <li>
      <a href="/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0000707" name="metrics">Metrics</a>
  </li>
  <li>
      <a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000707" name="comments">Comments</a>
  </li>
  <li>
      <a href="/article/related/info%3Adoi%2F10.1371%2Fjournal.pone.0000707" name="related">Related Content</a>
  </li>
  </ul>
</div>

<script type="text/javascript">
  var selected_tab = "article";
</script>
  <div id="figure-thmbs" class="carousel cf">
    <div class="wrapper">
      <div class="slider">
              <div class="item">
                <a href="#pone-0000707-g001" data-doi="info:doi/10.1371/journal.pone.0000707" data-uri="info:doi/10.1371/journal.pone.0000707.g001" title="Figure 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.g001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000707-t001" data-doi="info:doi/10.1371/journal.pone.0000707" data-uri="info:doi/10.1371/journal.pone.0000707.t001" title="Table 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.t001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000707-g002" data-doi="info:doi/10.1371/journal.pone.0000707" data-uri="info:doi/10.1371/journal.pone.0000707.g002" title="Figure 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.g002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
      </div>
    </div>
  </div>

  <div class="nav-col">
    <div class="nav" id="nav-article-page">
      <ul>
        <li class="nav-col-comments"><a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000707">Reader Comments (0)</a></li>
          <li id="nav-figures"><a data-doi="info:doi/10.1371/journal.pone.0000707" >Figures</a></li>
      </ul>
    </div>
  </div>

  <div class="article">







<div class="abstract"><a id="abstract0" name="abstract0" toc="abstract0" title="Abstract"></a><h2>Abstract</h2>
<h3>Background</h3>
<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1"></a><p>“FFM ME-TRAP” is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara) delivering the pre-erythrocytic malaria antigen ME-TRAP. Over nine months follow-up in our original study, there was no evidence that FFM ME-TRAP provided protection against malaria. The incidence of malaria was slightly higher in children who received FFM ME-TRAP, but this was not statistically significant (hazard ratio 1.5, 95% CI 1.0-2.3). Although the study was unblinded, another nine months follow-up was planned to monitor the incidence of malaria and other serious adverse events.</p>


<h3>Methods and Findings</h3>
<a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1"></a><p>405 children aged 1–6 yrs were initially randomized to vaccination with either FFM ME-TRAP or control (rabies vaccine). 380 children were still available for follow-up after the first nine months. Children were seen weekly and whenever they were unwell for nine months monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to parasitaemia &gt;2,500/µl. During the second nine months monitoring, 49 events met the primary endpoint (febrile malaria with parasites &gt;2,500/µl) in the Intention To Treat (ITT) group. 23 events occurred among the 189 children in the FFM ME-TRAP group, and 26 among the 194 children in the control group. In the full 18 months of monitoring, there were 63 events in the FFM ME-TRAP group and 60 in the control group (HR = 1.2, CI 0.84-1.73, p = 0.35). There was no evidence that the HR changed over the 18 months (test for interaction between time and vaccination p = 0.11).</p>


<h3>Conclusions</h3>
<a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1"></a><p>Vaccination with FFM ME-TRAP was not protective against malaria in this study. Malaria incidence during 18 months of surveillance was similar in both vaccine groups.</p>


<h3>Trial Registration</h3>
<a id="article1.front1.article-meta1.abstract1.sec4.p1" name="article1.front1.article-meta1.abstract1.sec4.p1"></a><p>Controlled-Trials.com <a href="http://www.controlled-trials.com/isrctn/trial/0/88335123.html">ISRCTN88335123</a></p>

</div>


<div class="articleinfo"><p><strong>Citation: </strong>Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, et al.  (2007) Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS ONE 2(8):
          e707.
            doi:10.1371/journal.pone.0000707</p><p><strong>Academic Editor: </strong>Colin Sutherland, London School of Hygiene &amp; Tropical Medicine, United Kingdom</p><p><strong>Received:</strong> May 10, 2007; <strong>Accepted:</strong> June 26, 2007; <strong>Published:</strong> August 15, 2007</p><p><strong>Copyright:</strong> © 2007 Bejon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>PB holds a Wellcome Trust training fellowship (073597), KM is supported by the Wellcome Trust and AVSH is a Wellcome Trust Principal Research Fellow. The study was funded by the Wellcome Trust and the Gates Malaria Partnership at the London School of Hygiene and Tropical Medicine. The funders had no role in trial design, conduct, analysis, presentation or decision to publish.</p><p><strong>Competing interests:</strong> The authors have declared that no competing interests exist.</p></div>





<div id="section1" class="section"><a id="s1" name="s1" toc="s1" title="Introduction"></a><h3>Introduction</h3><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1"></a><p>There were 515 million episodes of clinical <em>P. falciparum</em> malaria in 2002 <a href="#pone.0000707-Snow1">[1]</a>. Prime boost vaccination with FP9 (an attenuated fowlpox virus) then modified vaccinia virus Ankara (MVA), both recombinant for the pre-erythrocytic antigen construct ME-TRAP (the Multiple Epitope string and Thrombospondin Related Adhesion Protein, ME- TRAP <a href="#pone.0000707-Gilbert1">[2]</a>) is safe, immunogenic and partially protective in malaria-naïve adults exposed to experimental challenge <a href="#pone.0000707-Webster1">[3]</a>. We previously conducted a Phase 2b study of the FFM ME-TRAP regimen (i.e. two sequential FP9 ME-TRAP vaccinations followed by MVA ME-TRAP) to assess efficacy in children living in rural Kenya, and have reported the primary analysis <a href="#pone.0000707-Bejon1">[4]</a>. Local and systemic reactogenicity was mild. Immunogenicity was lower than that seen among partially protected volunteers in sporozoite challenge studies <a href="#pone.0000707-Webster1">[3]</a> and earlier phase 1 studies of children at lower malaria transmission intensities <a href="#pone.0000707-Bejon2">[5]</a>. There was no evidence of protection against malaria, (the incidence was higher among children vaccinated with FFM ME-TRAP, but this difference was not significant (the hazard ratio was 1.5, 95% CI 1.0-2.3, P = 0.14) <a href="#pone.0000707-Bejon1">[4]</a>.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2"></a><p>Although the study was unblinded at 9 months for the primary analysis of efficacy, the analysis plan specified continued surveillance for serious adverse events and malaria for a further period of 9 months.</p>
</div>

<div id="section2" class="section"><a id="s2" name="s2" toc="s2" title="Methods"></a><h3>Methods</h3><a id="article1.body1.sec2.p1" name="article1.body1.sec2.p1"></a><p>The protocols for this trial and supporting CONSORT checklist are available as supporting information; see <a href="#pone.0000707.s005">Checklist S1</a>, <a href="#pone.0000707.s001">Protocols S1</a>, <a href="#pone.0000707.s002">S2</a>, <a href="#pone.0000707.s003">S3</a>, and <a href="#pone.0000707.s004">Analysis Plan S1</a>.</p>

<h4>Study Design</h4>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1"></a><p>The study was randomised, controlled and double blind. Details of ethical approval are described previously <a href="#pone.0000707-Bejon1">[4]</a>.</p>
<a id="article1.body1.sec2.sec1.p2" name="article1.body1.sec2.sec1.p2"></a><p>405 children were randomized, and all received at least one dose of vaccine. Children were screened in February 2005, immunised between March 2005 and May 2005, and followed up until February 2006, when the study was unblinded. A further 9 months follow up was conducted on 387 children who were still available, until November 2006. No further cross-sectional bleeds were taken during this time.</p>


<h4>Participants</h4>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1"></a><p>The participating children were aged 1–6 years old when randomized in February 2005, healthy, and resident in the study area.</p>


<h4>Location</h4>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1"></a><p>The study was carried out in Junju sublocation in Kilifi District, on the Kenyan coast, as described previously <a href="#pone.0000707-Bejon1">[4]</a>.</p>


<h4>Interventions</h4>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1"></a><p>The trial vaccination regimen was a candidate prime boost malaria vaccination. Details have been described previously <a href="#pone.0000707-Bejon1">[4]</a>. Briefly, two sequential FP9 ME-TRAP vaccinations (5×10<sup>7</sup> plaque forming units) followed by MVA ME-TRAP vaccination (1.5×10<sup>8</sup> plaque forming units), given intradermally. The control was rabies vaccine (Aventis Pasteur, WISTAR strain), administered according to the same timings. Rabies was also given intradermally, at 0.25 IU. Vaccinations were spaced 4 weeks apart (acceptable range 3–5 weeks).</p>


<h4>Objectives</h4>
<a id="article1.body1.sec2.sec5.p1" name="article1.body1.sec2.sec5.p1"></a><p>The objectives of this extension of the original Phase 2b trial were to describe the distribution of febrile malaria by vaccination group, and to assess any latent safety issues.</p>


<h4>Outcomes</h4>
<a id="article1.body1.sec2.sec6.p1" name="article1.body1.sec2.sec6.p1"></a><p>Efficacy (Malaria episodes)</p>
<a id="article1.body1.sec2.sec6.p2" name="article1.body1.sec2.sec6.p2"></a><p>The primary endpoint was a clinical episode of malaria, defined as an axillary temperature greater than 37.5 degrees centigrade, with a <em>Plasmodium falciparum</em> parasitaemia greater than 2,500 parasites per ul. Episodes of malaria were identified as described previously <a href="#pone.0000707-Bejon1">[4]</a>.</p>


<h4>Randomization</h4>
<a id="article1.body1.sec2.sec7.p1" name="article1.body1.sec2.sec7.p1"></a><p>Full details of randomization have been described previously <a href="#pone.0000707-Bejon1">[4]</a>. Briefly, the investigators in Kenya enrolled children, and applied study numbers sequentially. A list of eligible children was ordered according to age and village, and matched to the list of randomization card numbers, generated in the UK.</p>


<h4>Blinding</h4>
<a id="article1.body1.sec2.sec8.p1" name="article1.body1.sec2.sec8.p1"></a><p>The nurses who administered vaccinations did not take part in any other trial related procedure, and were subsequently based in Kilifi District Hospital rather than the trial site. They drew up vaccinations according to the instructions in the randomisation envelope, and documented the vaccination in notes that were not available to the investigators until after unblinding</p>
<a id="article1.body1.sec2.sec8.p2" name="article1.body1.sec2.sec8.p2"></a><p>After the first 9 months monitoring the primary analysis was conducted. A cleaned, locked database was transmitted to the DSMB, and the statistician then transmitted the allocation code to the lead investigator, who then implemented the analysis plan. It was planned to conduct a further analysis of episodes of malaria after a further 9 months monitoring, despite having unblinded the trial. The results (no significant efficacy) were fed back to the study participants, and a strong view was expressed that study participants wished to be told which vaccines children had received. This was done. Continued monitoring was supervised by a second investigator, and the lead investigator played no further part in assessment of malaria episodes or collection of data. The second investigator did not have details of vaccination allocation, neither did the laboratory staff who read blood films. Data was cleaned by the second investigator before being locked, following which analysis was conducted by the lead investigator.</p>


<h4>Statistical methods</h4>
<a id="article1.body1.sec2.sec9.p1" name="article1.body1.sec2.sec9.p1"></a><p>The analysis plan was approved by the DSMB. The primary analysis was a log rank test comparing the time to the first or only episode of malaria (defined as fever with parasitaemia above 2500/µL) between the vaccination groups, stratified by age group, ITN (insecticide treated net) use and village, analysed by Intention To Treat. The hazard ratio and 95% confidence interval was estimated by Cox's regression adjusted for the same covariates. Age group was a categorical variable with three levels (1–2 years old, 2–5 years old, 5–6 years old). Village had 5 levels. ITN use was defined as sleeping under a treated net every night, which had less than three holes into which a finger could comfortably fit.</p>
<a id="article1.body1.sec2.sec9.p2" name="article1.body1.sec2.sec9.p2"></a><p>Poisson regression was used to estimate the incidence rate ratio taking into account all malaria episodes, adjusted for the same covariates. A period of 28 days after each malaria episode was deducted from the person time at risk, since individuals were assumed not to be at risk of malaria during this period. No further analysis is planned.</p>
<a id="article1.body1.sec2.sec9.p3" name="article1.body1.sec2.sec9.p3"></a><p>In order to assess interactions, data from each individual was split according to monitoring period. An interaction between vaccination and time of monitoring (first 9 months vs second 9 months) was then assessed for poisson regression and for survival analysis. Models with this interaction were compared with models without an interaction term using the likelihood ratio test.</p>

</div>

<div id="section3" class="section"><a id="s3" name="s3" toc="s3" title="Results"></a><h3>Results</h3>
<h4>Participant flow</h4>
<a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1"></a><p>405 children were randomized in May 2005, and 383 were still available for follow up after the first 9 months (<a href="#pone-0000707-g001">Figure 1</a>). 333 completed the second 9 months follow up.</p>
<div class="figure" id="pone-0000707-g001"><div class="img"><a name="pone-0000707-g001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.g001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000707" data-uri="info:doi/10.1371/journal.pone.0000707.g001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.g001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.g001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.g001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.g001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.g001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000707.g001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.g001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.g001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000707.g001.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 1.  <span>Trial Profile.</span></strong></p><a id="article1.body1.sec3.sec1.fig1.caption1.p1" name="article1.body1.sec3.sec1.fig1.caption1.p1"></a><p>After screening for eligibility, parents were invited to bring their children back to the dispensary for immunisation. Children were randomized on attending for vaccination. Of the 17 children who attended for the first, but not the final, vaccination, two had moved out of the area, and parents of the remaining 15 chose not to reattend. No severe adverse events were identified in this children. 8 children moved out of the area before 9 months monitoring was complete.</p>
<span>doi:10.1371/journal.pone.0000707.g001</span></div>

<h4>Baseline data</h4>
<a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1"></a><p>The treatment allocation groups at the start of the second 9 months monitoring were still well balanced with respect to baseline characteristics (<a href="#pone-0000707-t001">Table 1</a>).</p>
<div class="figure" id="pone-0000707-t001"><div class="img"><a name="pone-0000707-t001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.t001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000707" data-uri="info:doi/10.1371/journal.pone.0000707.t001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.t001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.t001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.t001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.t001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.t001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000707.t001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.t001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.t001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000707.t001.TIF"></span>)
                </a></li></ul></div><p><strong>Table 1.  <span>Covariates by vaccination group at the beginning of the second 9 months monitoring.</span></strong></p><span>doi:10.1371/journal.pone.0000707.t001</span></div>

<h4>Numbers analyzed</h4>
<a id="article1.body1.sec3.sec3.p1" name="article1.body1.sec3.sec3.p1"></a><p>Of the 383 children followed up in the second 9 months, 342 were from the original According To Protocol analysis group. All 383 were part of the Intention To Treat group.</p>


<h4>Outcomes and estimation</h4>
<a id="article1.body1.sec3.sec4.p1" name="article1.body1.sec3.sec4.p1"></a><p>The primary analysis for this study has already been conducted <a href="#pone.0000707-Bejon1">[4]</a>. During the second 9 months monitoring, there were 49 events that met the primary endpoint (febrile malaria with parasites &gt;2,500/µl) in the ITT group. 23 of these occurred among the 189 children in the FFM ME-TRAP group, and 26 among the 194 children in the rabies control group (logrank test p = 0.59, p = 0.67 when stratified by age, village and ITN use). In the full 18 months of monitoring, there were 63 events in the FFM ME-TRAP group and 60 in the control group (p = 0.46, p = 0.35 when stratified by covariates). A Kaplan Meier plot of the ITT group is shown in <a href="#pone-0000707-g002">figure 2</a>.</p>
<div class="figure" id="pone-0000707-g002"><div class="img"><a name="pone-0000707-g002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.g002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000707" data-uri="info:doi/10.1371/journal.pone.0000707.g002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000707.g002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.g002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.g002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.g002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.g002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000707.g002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000707.g002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000707.g002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000707.g002.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 2.  <span>Primary analysis of efficacy.</span></strong></p><a id="article1.body1.sec3.sec4.fig1.caption1.p1" name="article1.body1.sec3.sec4.fig1.caption1.p1"></a><p>The probability of remaining free of clinical malaria is plotted over the 18 months of monitoring (ITT analysis). Numbers of children at risk are given below the Kaplan Meier plot. The endpoint is &gt;2,500 parasites per microlitre and fever. HR = 0.84, 95% CI 0.47-1.49, p = 0.59</p>
<span>doi:10.1371/journal.pone.0000707.g002</span></div><a id="article1.body1.sec3.sec4.p2" name="article1.body1.sec3.sec4.p2"></a><p>When analysis was restricted According To Protocol, there were 52 events among 170 children in the FFM ME-TRAP group, compared with 54 among 172 children in the rabies control group (p = 0.94, p = 0.95 adjusted).</p>


<h4>Survival Analysis (Cox Regression)</h4>
<a id="article1.body1.sec3.sec5.p1" name="article1.body1.sec3.sec5.p1"></a><p>The hazard ratio (HR) for the effect of vaccination, estimated using Cox regression, was 1.2 (95% CI 0.84-1.73, p = 0.35) over the full 18 months of monitoring. The HR during the first 9 months was 1.52 (1–2.31, p = 0.14), followed by 0.84 (0.47–1.49, p = 0.59) during the second 9 months. When analysis was restricted to ATP, the HRs were 1.06 (0.72–1.56 p = 0.94), 1.31 (0.83–2.08, p = 0.35) and 0.72 (0.39–1.34, p = 0.31) for the full 18 months, first 9 months and second 9 months monitoring, respectively. The difference in HRs between the two time periods was not statistically significant (the likelihood ratio test for the interaction between time period and vaccination group gave p = 0.11 and p = 0.15 for ITT and ATP analyses respectively).</p>


<h4>Multiple Episodes</h4>
<a id="article1.body1.sec3.sec6.p1" name="article1.body1.sec3.sec6.p1"></a><p>During 18 months monitoring of the ITT cohort there were 170 episodes of febrile malaria with parasitaemia &gt;2,500/µl among 383 children. This comprised 0.35 episodes per Person Year At Risk among children given FFM ME-TRAP, and 0.29 among children given the control vaccination.</p>
<a id="article1.body1.sec3.sec6.p2" name="article1.body1.sec3.sec6.p2"></a><p>The Incidence Rate Ratios for the effect of vaccination were 1.06 (CI 0.76-1.48, p = 0.75) during the first 18 months, 1.58 (CI 1.08-2.32, p = 0.017) during the first 9 months and 0.8 (0.46–1.36, p = 0.42) during the second 9 months. Among the ATP cohort the IRRs were 1.06 (0.76–1.48, p = 0.75), 1.36 (0.89–2.06, p = 0.16) and 0.67 (0.38–1.19, p = 0.17) for the full 18 months, first 9 months and second 9 months monitoring, respectively. The likelihood ratio test for the interaction between vaccine group and time period gave p = 0.051 and p = 0.093 for ITT and ATP analysis respectively.</p>


<h4>Adverse Events</h4>
<a id="article1.body1.sec3.sec7.p1" name="article1.body1.sec3.sec7.p1"></a><p>8 Further serious adverse events were detected during the second 9 months of follow up. Among FFM ME-TRAP vaccinees there were episodes of pneumonia, dysentery, malaria with multiple seizures and a snake bite which required hospital admissions. Among control vaccinees there were two episodes of gastroenteritis with dehydration, an episode of malaria with multiple seizures and a Stevens Johnson reaction (associated with co-trimoxazole use). All adverse events resolved without sequelae, and there were no deaths in either group.</p>

</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3>
<h4>Interpretation</h4>
<a id="article1.body1.sec4.sec1.p1" name="article1.body1.sec4.sec1.p1"></a><p>We have previously reported the primary analysis after 9 months post-vaccination monitoring for episodes of malaria <a href="#pone.0000707-Bejon1">[4]</a>, during which there was no evidence of protection against malaria. The incidence was higher among children vaccinated with FFM ME-TRAP, but this difference was not significant. We report here a further 9 months monitoring of the same children, during which the incidence of malaria episodes was similar in both groups.</p>
<a id="article1.body1.sec4.sec1.p2" name="article1.body1.sec4.sec1.p2"></a><p>The primary analysis considers time to first episode. In this analysis children do not contribute further to the analysis after an episode of malaria, which could potentially cause a bias in the estimation of the hazard ratio in the second period. However, similar results were obtained when multiple episodes were analyzed.</p>
<a id="article1.body1.sec4.sec1.p3" name="article1.body1.sec4.sec1.p3"></a><p>The primary analysis had already been conducted. The analysis here is therefore considered secondary. Furthermore, these data were acquired after the study had been unblinded. Measures were taken to reduce the impact of this on the integrity of the study; an investigator not involved in the primary analysis oversaw the second 9 months of monitoring, and blood films were read in the laboratory with reference to only study subject numbers without knowledge of vaccination group. The lead investigator who had conducted the primary analysis was not involved in continued follow up, and conducted the analysis presented here after being sent a cleaned database. That no efficacy was seen on the primary analysis was communicated to study participants, and so vaccine allocation was perhaps unlikely to bias health seeking behaviour. A similar number of follow up visits were completed among children allocated to either vaccination (4,958 visits among FFM ME-TRAP vaccinees vs 5,130 among controls), and a similar number presented for assessment of fever between visits (1,086 among FFM ME-TRAP vaccinees vs 1,095 among controls), p = 0.58). Nevertheless, a subtle impact on health seeking behaviour cannot be excluded, and our findings here must be treated with appropriate caution.</p>
<a id="article1.body1.sec4.sec1.p4" name="article1.body1.sec4.sec1.p4"></a><p>Borderline significance on log likelihood testing for interactions between monitoring period and vaccination was seen. However, this was one of multiple analyses for interactions. The other 3 tests yielded less significant findings, and the study was no longer blind. There is insufficient evidence to conclude there might have been an interaction between vaccination and time (i.e. the effect, or lack of effect, of vaccination was constant throughout the duration of the study). This suggests that the variations in hazard during the monitoring period probably represent chance alone.</p>
<a id="article1.body1.sec4.sec1.p5" name="article1.body1.sec4.sec1.p5"></a><p>After the primary analysis of this trial we considered the formal possibility that transforming growth factor β production <a href="#pone.0000707-Walther1">[6]</a> and anti-inflammatory responses <a href="#pone.0000707-Flanagan1">[7]</a> induced by vaccination might increase susceptibility to malaria. However, there was no indication that higher T cell responses predicted greater susceptibility to malaria, suggesting that there was not a causal link, and the increase in risk was not significant during primary analysis <a href="#pone.0000707-Bejon1">[4]</a>. The convergence of Incidence Rates and Hazards seen during the second 9 months of monitoring provides further reassurance. Since the vaccinated children are now aged 3–8 years, and the incidence of malaria is expected to be lower still, continued analysis of episodes of malaria by vaccination group is not planned.</p>

</div>

<div id="section5" class="section"><a id="s5" name="s5" toc="s5" title="Supporting Information"></a><h3>Supporting Information</h3><div class="figshare_widget" doi="10.1371/journal.pone.0000707"></div><a name="pone.0000707.s001" id="pone.0000707.s001"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0000707.s001">Protocol S1. </a></strong></p><a id="article1.body1.sec5.supplementary-material1.caption1.p1" name="article1.body1.sec5.supplementary-material1.caption1.p1"></a><p class="preSiDOI">Protocol Under Which Further 9 Months Follow up was Conducted</p>
<p class="siDoi">doi:10.1371/journal.pone.0000707.s001</p><a id="article1.body1.sec5.supplementary-material1.caption1.p2" name="article1.body1.sec5.supplementary-material1.caption1.p2"></a><p class="postSiDOI">(4.42 MB PDF)</p>
<a name="pone.0000707.s002" id="pone.0000707.s002"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0000707.s002">Protocol S2. </a></strong></p><a id="article1.body1.sec5.supplementary-material2.caption1.p1" name="article1.body1.sec5.supplementary-material2.caption1.p1"></a><p class="preSiDOI">Protocol for ongoing study</p>
<p class="siDoi">doi:10.1371/journal.pone.0000707.s002</p><a id="article1.body1.sec5.supplementary-material2.caption1.p2" name="article1.body1.sec5.supplementary-material2.caption1.p2"></a><p class="postSiDOI">(4.42 MB DOC)</p>
<a name="pone.0000707.s003" id="pone.0000707.s003"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0000707.s003">Protocol S3. </a></strong></p><a id="article1.body1.sec5.supplementary-material3.caption1.p1" name="article1.body1.sec5.supplementary-material3.caption1.p1"></a><p class="preSiDOI">Original protocol</p>
<p class="siDoi">doi:10.1371/journal.pone.0000707.s003</p><a id="article1.body1.sec5.supplementary-material3.caption1.p2" name="article1.body1.sec5.supplementary-material3.caption1.p2"></a><p class="postSiDOI">(0.31 MB DOC)</p>
<a name="pone.0000707.s004" id="pone.0000707.s004"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0000707.s004">Analysis Plan S1. </a></strong></p><a id="article1.body1.sec5.supplementary-material4.caption1.p1" name="article1.body1.sec5.supplementary-material4.caption1.p1"></a><p class="preSiDOI">Analysis Plan for second 9 months follow up</p>
<p class="siDoi">doi:10.1371/journal.pone.0000707.s004</p><a id="article1.body1.sec5.supplementary-material4.caption1.p2" name="article1.body1.sec5.supplementary-material4.caption1.p2"></a><p class="postSiDOI">(0.03 MB DOC)</p>
<a name="pone.0000707.s005" id="pone.0000707.s005"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0000707.s005">Checklist S1. </a></strong></p><a id="article1.body1.sec5.supplementary-material5.caption1.p1" name="article1.body1.sec5.supplementary-material5.caption1.p1"></a><p class="preSiDOI">CONSORT checklist</p>
<p class="siDoi">doi:10.1371/journal.pone.0000707.s005</p><a id="article1.body1.sec5.supplementary-material5.caption1.p2" name="article1.body1.sec5.supplementary-material5.caption1.p2"></a><p class="postSiDOI">(0.05 MB DOC)</p>
</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>The participants and their parents are thanked. The Junju dispensary committee facilitated the study. The study was performed with the permission of KEMRI National Ethics Committees, and COREC, the NHS Central Office for Research Ethics Committees. The study was published with the permission of the Director of KEMRI. The DSMB members were David Mabey (chair), Tim Peto, Lucy Dorrell and Kathryn Maitland.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: PB PM TM KM AH TL GF NP. Performed the experiments: SG TM EO NP. Analyzed the data: PB PM. Wrote the paper: PB PM AH. Other: Supplied and provided quality assurance of vaccines used in clinical trial: SG. Enrolled patients: PB. PB's PhD supervisor onsite: KM. PB's PhD supervisor: AH. Clinical Trials Support: TL.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0000707-Snow1" id="pone.0000707-Snow1"></a>Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature  434: 214–217.  <ul class="find" data-citedArticleID="974790" data-doi="10.1038/nature03342"><li><a href="http://dx.doi.org/10.1038/nature03342" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+global+distribution+of+clinical+episodes+of+Plasmodium+falciparum+malaria." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+global+distribution+of+clinical+episodes+of+Plasmodium+falciparum+malaria.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">2.
              </span><a name="pone.0000707-Gilbert1" id="pone.0000707-Gilbert1"></a>Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, et al.  (1997) A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol  15: 1280–1284.  <ul class="find" data-citedArticleID="974782" data-doi="10.1038/nbt1197-1280"><li><a href="http://dx.doi.org/10.1038/nbt1197-1280" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+protein+particle+vaccine+containing+multiple+malaria+epitopes." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+protein+particle+vaccine+containing+multiple+malaria+epitopes.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0000707-Webster1" id="pone.0000707-Webster1"></a>Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, et al.  (2005) Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A  102: 4836–4841.  <ul class="find" data-citedArticleID="974778" data-doi="10.1073/pnas.0406381102"><li><a href="http://dx.doi.org/10.1073/pnas.0406381102" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Enhanced+T+cell-mediated+protection+against+malaria+in+human+challenges+by+using+the+recombinant+poxviruses+FP9+and+modified+vaccinia+virus+Ankara." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Enhanced+T+cell-mediated+protection+against+malaria+in+human+challenges+by+using+the+recombinant+poxviruses+FP9+and+modified+vaccinia+virus+Ankara.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0000707-Bejon1" id="pone.0000707-Bejon1"></a>Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, et al.  (2006) A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS Clin Trials  1: e29.  <ul class="find" data-citedArticleID="974786" data-doi="10.1371/journal.pctr.0010029"><li><a href="http://dx.doi.org/10.1371/journal.pctr.0010029" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+Phase+2b+Randomised+Trial+of+the+Candidate+Malaria+Vaccines+FP9+ME-TRAP+and+MVA+ME-TRAP+among+Children+in+Kenya." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+Phase+2b+Randomised+Trial+of+the+Candidate+Malaria+Vaccines+FP9+ME-TRAP+and+MVA+ME-TRAP+among+Children+in+Kenya.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0000707-Bejon2" id="pone.0000707-Bejon2"></a>Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, et al.  (2006) Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1–6 year old children in a malaria endemic area. Vaccine.   <ul class="find-nolinks"></ul></li><li><span class="label">6.
              </span><a name="pone.0000707-Walther1" id="pone.0000707-Walther1"></a>Walther M, Tongren JE, Andrews L, Korbel D, King E, et al.  (2005) Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity  23: 287–296.  <ul class="find" data-citedArticleID="974780" data-doi="10.1016/j.immuni.2005.08.006"><li><a href="http://dx.doi.org/10.1016/j.immuni.2005.08.006" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Upregulation+of+TGF-beta%2C+FOXP3%2C+and+CD4%2BCD25%2B+regulatory+T+cells+correlates+with+more+rapid+parasite+growth+in+human+malaria+infection." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Upregulation+of+TGF-beta%2C+FOXP3%2C+and+CD4%2BCD25%2B+regulatory+T+cells+correlates+with+more+rapid+parasite+growth+in+human+malaria+infection.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0000707-Flanagan1" id="pone.0000707-Flanagan1"></a>Flanagan KL, Plebanski M, Odhiambo K, Sheu E, Mwangi T, et al.  (2006) Cellular reactivity to the P. falciparum protein TRAP in adult Kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am J Trop Med Hyg  74: 367–375.  <ul class="find" data-citedArticleID="974788"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Cellular+reactivity+to+the+P.+falciparum+protein+TRAP+in+adult+Kenyans%3A+novel+epitopes%2C+complex+cytokine+patterns%2C+and+the+impact+of+natural+antigenic+variation.&amp;auth=&amp;atitle=Cellular+reactivity+to+the+P.+falciparum+protein+TRAP+in+adult+Kenyans%3A+novel+epitopes%2C+complex+cytokine+patterns%2C+and+the+impact+of+natural+antigenic+variation." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cellular+reactivity+to+the+P.+falciparum+protein+TRAP+in+adult+Kenyans%3A+novel+epitopes%2C+complex+cytokine+patterns%2C+and+the+impact+of+natural+antigenic+variation." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cellular+reactivity+to+the+P.+falciparum+protein+TRAP+in+adult+Kenyans%3A+novel+epitopes%2C+complex+cytokine+patterns%2C+and+the+impact+of+natural+antigenic+variation.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.XML" value="38574"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.PDF" value="178421"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g001.PNG_L" value="311313"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g001.PNG_M" value="94669"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g001.PNG_S" value="8640"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g001.TIF" value="577414"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g001.PNG_I" value="12620"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.t001.PNG_L" value="54174"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.t001.PNG_M" value="146055"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.t001.PNG_S" value="18806"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.t001.TIF" value="327778"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.t001.PNG_I" value="22505"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g002.PNG_L" value="288775"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g002.PNG_M" value="163126"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g002.PNG_S" value="12302"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g002.TIF" value="476906"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.g002.PNG_I" value="20426"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.s001.PDF" value="4417295"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.s002.DOC" value="4417295"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.s003.DOC" value="305664"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.s004.DOC" value="30208"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000707.s005.DOC" value="48640"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000707&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000707" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000707&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0000707&volume=&issue=&title=Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya&author_name=Philip%20Bejon%2C%20Edna%20Ogada%2C%20Tabitha%20Mwangi%2C%20Paul%20Milligan%2C%20Trudie%20Lang%2C%20Greg%20Fegan%2C%20Sarah%20C.%20Gilbert%2C%20Norbert%20Peshu%2C%20Kevin%20Marsh%2C%20Adrian%20V.S.%20Hill&start_page=1&end_page=5" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000707" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000707" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0000707" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000707&amp;t=Extended%20Follow-Up%20Following%20a%20Phase%202b%20Randomized%20Trial%20of%20the%20Candidate%20Malaria%20Vaccines%20FP9%20ME-TRAP%20and%20MVA%20ME-TRAP%20among%20Children%20in%20Kenya" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000707&title=Extended%20Follow-Up%20Following%20a%20Phase%202b%20Randomized%20Trial%20of%20the%20Candidate%20Malaria%20Vaccines%20FP9%20ME-TRAP%20and%20MVA%20ME-TRAP%20among%20Children%20in%20Kenya&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000707&amp;title=Extended%20Follow-Up%20Following%20a%20Phase%202b%20Randomized%20Trial%20of%20the%20Candidate%20Malaria%20Vaccines%20FP9%20ME-TRAP%20and%20MVA%20ME-TRAP%20among%20Children%20in%20Kenya" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000707" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0000707&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0000707';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Extended%20Follow-Up%20Following%20a%20Phase%202b%20Randomized%20Trial%20of%20the%20Candidate%20Malaria%20Vaccines%20FP9%20ME-TRAP%20and%20MVA%20ME-TRAP%20among%20Children%20in%20Kenya http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000707" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0000707" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">





















          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Adverse+events%22" title="Search for articles in the subject area:'Adverse events'"><div class="flagText">Adverse events</div></a>
              <div data-categoryid="24207" data-articleid="24252"
                   data-categoryname="Adverse events"
                   class="flagImage" title="Flag 'Adverse events' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Antigens%22" title="Search for articles in the subject area:'Antigens'"><div class="flagText">Antigens</div></a>
              <div data-categoryid="32115" data-articleid="24252"
                   data-categoryname="Antigens"
                   class="flagImage" title="Flag 'Antigens' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Children%22" title="Search for articles in the subject area:'Children'"><div class="flagText">Children</div></a>
              <div data-categoryid="40327" data-articleid="24252"
                   data-categoryname="Children"
                   class="flagImage" title="Flag 'Children' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Malaria%22" title="Search for articles in the subject area:'Malaria'"><div class="flagText">Malaria</div></a>
              <div data-categoryid="47353" data-articleid="24252"
                   data-categoryname="Malaria"
                   class="flagImage" title="Flag 'Malaria' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Malarial+parasites%22" title="Search for articles in the subject area:'Malarial parasites'"><div class="flagText">Malarial parasites</div></a>
              <div data-categoryid="42885" data-articleid="24252"
                   data-categoryname="Malarial parasites"
                   class="flagImage" title="Flag 'Malarial parasites' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Rabies%22" title="Search for articles in the subject area:'Rabies'"><div class="flagText">Rabies</div></a>
              <div data-categoryid="48857" data-articleid="24252"
                   data-categoryname="Rabies"
                   class="flagImage" title="Flag 'Rabies' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Vaccination+and+immunization%22" title="Search for articles in the subject area:'Vaccination and immunization'"><div class="flagText">Vaccination and immunization</div></a>
              <div data-categoryid="31857" data-articleid="24252"
                   data-categoryname="Vaccination and immunization"
                   class="flagImage" title="Flag 'Vaccination and immunization' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Vaccines%22" title="Search for articles in the subject area:'Vaccines'"><div class="flagText">Vaccines</div></a>
              <div data-categoryid="31861" data-articleid="24252"
                   data-categoryname="Vaccines"
                   class="flagImage" title="Flag 'Vaccines' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=9857'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=6867'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=3302&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>


</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
